Together, these observations suggest that CDK4/6 inhibition reprograms mitochondrial metabolism in melanoma cells via both glutamine and fatty acid-oxidation-dependent pathways; however, only reprogrammed glutamine metabolism appears significant with regard to CDK4/6 inhibitor sensitivity and the proliferative response. The gene discussed is CDK4; the disease is melanoma.